New Melanoma Treatment Might Delay Cancer Progression - Consumer Health News | HealthDay

New drug treatment drug treatment, Download as PDF

By targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said.

New dimensions in the treatment of muscle spasticity after stroke and nervous system defects First-in-class antispastic drug candidate to reach clinical phase is published in the prestigious life science journal, Cell.

Melanoma is the most serious, and often deadly, form of skin cancer. In about half of patients with melanoma that has spread, tumor growth is caused by genetic mutations that keep the BRAF protein -- part of the MAPK cell growth pathway -- constantly activated.

Patients with a documented history of chronic non-malignant neuropathic pain at Visit 1 3. Stable individual regular standard treatment regimen for chronic neuropathic pain, i. Use of rescue medication for neuropathic pain including topical treatments, physical measures etc.

Drugs that inhibit BRAF activity can rapidly stop and reverse tumor growth in about 90 percent of patients. But the response is temporary in most cases, and tumor growth resumes in six or seven months, the researchers explained. The phase 1 and 2 study was sponsored by GlaxoSmithKline, which developed both drugs.

new drug treatment drug treatment

In fact, the combination was at least twice as effective as BRAF inhibition alone," he said. One expert agreed that the results were encouraging.

new drug treatment drug treatment

These drugs can be safely combined, and the survival was significantly improved without untoward side effects," said Dr. The study was conducted at 14 sites in the United States new drug treatment drug treatment Australia and included patients who received different dose combinations of the drugs: two daily milligram mg doses of dabrafenib plus one 2 mg dose of trametinib; the same dabrafenib dose with a 1 mg dose of trametinib; or treatment with dabrafenib alone. Patients who received dabrafenib alone were able to receive the full-dose combination treatment if their cancer resumed progression.

new drug treatment drug treatment

Treatment with both combinations of dabrafenib and trametinib led to a four-month longer delay in drug resistance than treatment with dabrafenib alone. After one year of treatment, 41 percent of patients receiving the full-dose combination treatment had no progression of their melanoma, compared with 9 percent of those receiving dabrafenib alone.

Among patients receiving the combination treatment, the development of side san-cukorbetegség such as skin rash and a less dangerous type of skin cancer called squamous cell carcinoma was similar to that typically seen in patients taking only one of the drugs.

New hope in treating PTSD with psychedelic drugs

The drug combination is now being tested in a larger phase 3 study, which is required for U. Food and Drug Administration approval. More information The American Cancer Society has more about melanoma.

About Epilepsy Epilepsy is a medical condition that produces seizures that affect a variety of mental and physical functions. A patient is considered to have epilepsy after two or more unprovoked seizures, which occur when a brief, strong surge of electrical activity affects part or all of the brain. An individual may experience various symptoms, from convulsions and loss of consciousness, to some that are not always recognized as seizures, such as blank staring, lip smacking, or jerking movements of arms and legs. Epilepsy can develop at any age and 0. It has been reported that epilepsy affects nearly 1 million people in Japan, 2.